| Website | endosense.com |
| @TactiCath | |
| Category | BioTech |
| Phone | 41-22-306-19-60 |
| info@endosense.com | |
| Employees | |
| Founded | 2003 |
| TOTAL | $80.6M |
| FUNDING TOTAL | $80.6M |
| Series B, 10/09 Edmond de Rothschild Venture Capital NeoMed Gimv VI Partners Sectoral Asset Management Ysios Capital DEFI Gestion | $36M |
| Series C, 11/12 NGN Capital Edmond de Rothschild Investment Partners Neomed Management Gimv VI Partners Sectoral Asset Management Ysios Capital Partners Initiative Capital | $40.3M |
| Series C, 3/13 | $4.3M |
Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense’s TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
